Sloning BioTechnology Overview

  • Founded
  • 2000
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $25.4M
Latest Deal Amount

Sloning BioTechnology General Information

Description

Provider of production platform to synthesize DNA molecules. The company's offers fully-automated Sloning technology for gene synthesis. The company also supplies synthetic biology tools.

Contact Information

Website
www.sloning.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Acquirer
Primary Office
  • Zeppelinstrasse 4
  • 82178 Puchheim
  • Germany
+49 089 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sloning BioTechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 09-Oct-2010 $25.4M 000.00 000.00 Completed Generating Revenue
6. Later Stage VC 01-Sep-2009 000.00 Completed Generating Revenue
5. Later Stage VC (Series E) 01-Nov-2007 00.00 000.00 Completed Generating Revenue
4. Early Stage VC 18-May-2005 00.000 00.000 Completed Product Development
3. Grant 05-Aug-2003 00.00 00.000 Completed
2. Early Stage VC (Series B) 15-Apr-2003 $4.61M $4.61M Completed Generating Revenue
1. Early Stage VC 01-Jan-2001 Completed Product Development
To view Sloning BioTechnology’s complete valuation and funding history, request access »

Sloning BioTechnology Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3i Group PE/Buyout Minority 000 0000 000000 0
Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft PE/Buyout Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
KfW Group Investment Bank Minority 000 0000 000000 0
LBBW Venture Capital Corporate Venture Capital Minority 000 0000 000000 0
To view Sloning BioTechnology’s complete investors history, request access »